search
Back to results

Efficacy Study of Tissucol/Tisseel Fibrin Sealant to Treat Inguinal Hernia

Primary Purpose

Inguinal Hernia

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
standardized Lichtenstein technique
Sponsored by
University of Milan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Inguinal Hernia focused on measuring Tissucol, Tisseel, Lichtenstein, hernia, inguinal

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Signed informed consent obtained from the subject prior to participation in the study Active males over the age of 18 years and below 80 years Experiencing an uncomplicated unilateral primary inguinal hernia or experiencing an uncomplicated bilateral hernia provided that only one hernia is operated during the 12 months of study follow-up Subjects eligible for elective inguinal hernia repair using Lichtenstein technique. Exclusion Criteria: Recurrent, scrotal, incarcerated or femoral hernias Hernia types L3 and M3 according the EHS classification BMI equal or more than 35 Concomitant abdominal surgery Ongoing long term analgesic or steroid treatment Patients under Clopidogrel or Warfarin (can be switched to LMW sub-cutaneous heparin) Known abuse of alcohol or drugs Liver cirrhosis (Child C) Previous treatment or Hypersensitivity to bovine aprotinin Known immunodeficiency Severely compromised physical or psychological health, that in the investigator's opinion will affect patient compliance Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days

Sites / Locations

  • Gasthuisberg University Hospitals KUL
  • Copenhagen university hospital, Gentofte
  • Hôpital Jean Verdier
  • St. Hildegardis-Krankenhaus
  • Clinica Nuestra Senora del Rosario
  • Derriford Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

1

2

Arm Description

Tissel group

Suture group

Outcomes

Primary Outcome Measures

Combined endpoint evaluating incidence of disabling complications:chronic pain and/or numbness and/or groin discomfort assessed 1 year after surgery.

Secondary Outcome Measures

Recurrence
Overall wound-healing complication rate (bleeding complications, bruising, seroma, wound infection, mesh infection)
Early postoperative pain at W1 and M1
Mid-term postoperative pain at M6
Incidence of patients without pain at M1, M6 and M12
Use of analgesic drugs
Patient's satisfaction
Safety (incidence of adverse events)
Quality of Life assessed by SF12 pre-operatively or at D-1, M1, M6 and M12
Hospital stay (hour or Days) and time to return to normal activities
A subgroup analysis will be done for patients receiving pre-operatively aspirin or LMW sub-cutaneous heparin.
The study will be blinded for the patient and for the physician evaluating the pain.

Full Information

First Posted
March 22, 2006
Last Updated
February 12, 2009
Sponsor
University of Milan
Collaborators
Baxter Healthcare Corporation, Pr Giampiero CAMPANELLI
search

1. Study Identification

Unique Protocol Identification Number
NCT00306839
Brief Title
Efficacy Study of Tissucol/Tisseel Fibrin Sealant to Treat Inguinal Hernia
Official Title
Prospective, Controlled, Randomized Study to Evaluate Pain and Further Disabling Complications in Patients Undergoing Lichtenstein Technique for Primary Inguinal Hernia Repair by Fixing the Mesh With Fibrin Sealant Versus Sutures
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Milan
Collaborators
Baxter Healthcare Corporation, Pr Giampiero CAMPANELLI

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate mid and long term postoperative pain and further disabling complications in open inguinal hernia repair by Lichtenstein technique after mesh fixation with fibrin sealant (FS), compared to mesh fixation with sutures.
Detailed Description
Subjects in the FS group will be operated by Lichtenstein technique, with mesh fixation by fibrin sealant. Subjects in control group will be operated with conventional Lichtenstein technique (mesh fixation by sutures). Hernia repair will be performed according to standardized Lichtenstein technique, a technique for tension free hernioplasty. A Polypropylene, heavyweight, macroporous mesh will be used (8x15 cm) tailored to individual patients requirement. The different ways of mesh fixation will be randomly assigned within 24 hours before the operation. In the FS group, the two tails of the mesh will be fixed together in overlapping their edges and by surrounding the cord. The edges will be joined up to by 1 suture. No other sutures will be used. First the mesh will be put correctly in place. A small spot (0.5ml) of FS will be applied on the pubis under the mesh without spray then the remaining part (3,5ml) over the mesh on the entire surface in a thin uniform layer by spray. 2 ml Tissucol-Tisseel (4 ml of fibrin sealant) will be used per mesh. In the control group, the mesh will be fixed in a conventional manner. Nerve resection (if occurred) will be recorded; it should be avoided.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inguinal Hernia
Keywords
Tissucol, Tisseel, Lichtenstein, hernia, inguinal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
325 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Other
Arm Description
Tissel group
Arm Title
2
Arm Type
Other
Arm Description
Suture group
Intervention Type
Procedure
Intervention Name(s)
standardized Lichtenstein technique
Primary Outcome Measure Information:
Title
Combined endpoint evaluating incidence of disabling complications:chronic pain and/or numbness and/or groin discomfort assessed 1 year after surgery.
Secondary Outcome Measure Information:
Title
Recurrence
Title
Overall wound-healing complication rate (bleeding complications, bruising, seroma, wound infection, mesh infection)
Title
Early postoperative pain at W1 and M1
Title
Mid-term postoperative pain at M6
Title
Incidence of patients without pain at M1, M6 and M12
Title
Use of analgesic drugs
Title
Patient's satisfaction
Title
Safety (incidence of adverse events)
Title
Quality of Life assessed by SF12 pre-operatively or at D-1, M1, M6 and M12
Title
Hospital stay (hour or Days) and time to return to normal activities
Title
A subgroup analysis will be done for patients receiving pre-operatively aspirin or LMW sub-cutaneous heparin.
Title
The study will be blinded for the patient and for the physician evaluating the pain.

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent obtained from the subject prior to participation in the study Active males over the age of 18 years and below 80 years Experiencing an uncomplicated unilateral primary inguinal hernia or experiencing an uncomplicated bilateral hernia provided that only one hernia is operated during the 12 months of study follow-up Subjects eligible for elective inguinal hernia repair using Lichtenstein technique. Exclusion Criteria: Recurrent, scrotal, incarcerated or femoral hernias Hernia types L3 and M3 according the EHS classification BMI equal or more than 35 Concomitant abdominal surgery Ongoing long term analgesic or steroid treatment Patients under Clopidogrel or Warfarin (can be switched to LMW sub-cutaneous heparin) Known abuse of alcohol or drugs Liver cirrhosis (Child C) Previous treatment or Hypersensitivity to bovine aprotinin Known immunodeficiency Severely compromised physical or psychological health, that in the investigator's opinion will affect patient compliance Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
CAMPANELLI Giampiero, Professor
Official's Role
Study Chair
Facility Information:
Facility Name
Gasthuisberg University Hospitals KUL
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Copenhagen university hospital, Gentofte
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Hôpital Jean Verdier
City
Bondy
ZIP/Postal Code
93143
Country
France
Facility Name
St. Hildegardis-Krankenhaus
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Clinica Nuestra Senora del Rosario
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
Derriford Hospital
City
Plymouth
ZIP/Postal Code
PL6 8DH
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
22395092
Citation
Campanelli G, Pascual MH, Hoeferlin A, Rosenberg J, Champault G, Kingsnorth A, Miserez M. Randomized, controlled, blinded trial of Tisseel/Tissucol for mesh fixation in patients undergoing Lichtenstein technique for primary inguinal hernia repair: results of the TIMELI trial. Ann Surg. 2012 Apr;255(4):650-7. doi: 10.1097/SLA.0b013e31824b32bf.
Results Reference
derived

Learn more about this trial

Efficacy Study of Tissucol/Tisseel Fibrin Sealant to Treat Inguinal Hernia

We'll reach out to this number within 24 hrs